These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38241371)

  • 1. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
    Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
    Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
    LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
    J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
    Tabachnick-Cherny S; Pulliam T; Rodriguez HJ; Fan X; Hippe DS; Jones DC; Moshiri AS; Smythe KS; Kulikauskas RM; Zaba LC; Paulson KG; Nghiem P
    Clin Cancer Res; 2024 Mar; 30(6):1189-1199. PubMed ID: 37851052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
    Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
    Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
    Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
    J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
    Marchand A; Kervarrec T; Bhatia S; Samimi M
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
    Barkdull S; Brownell I
    Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
    Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
    Lien SC; Ly D; Yang SYC; Wang BX; Clouthier DL; St Paul M; Gadalla R; Noamani B; Garcia-Batres CR; Boross-Harmer S; Bedard PL; Pugh TJ; Spreafico A; Hirano N; Razak ARA; Ohashi PS
    Nat Commun; 2024 Feb; 15(1):1094. PubMed ID: 38321065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma.
    Nakamura M; Nagase K; Yoshimitsu M; Magara T; Nojiri Y; Kato H; Kobayashi T; Teramoto Y; Yasuda M; Wada H; Ozawa T; Umemori Y; Ogata D; Morita A
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.